PharmAthene

PharmAthene, Inc. (NYSE MKT: PIP), formed in March 2001, is pursuing its mission to advance the Nation’s health security by developing novel medical solutions that utilize cutting-edge biotechnology to offer improvements in safety, efficacy and cost-effectiveness over current therapies. The Company’s strategy focuses on acquiring and developing new, best-in-class products and technologies identified by the United States and other governments as urgent procurement priorities. Since its inception in 2001, PharmAthene has obtained non-dilutive U.S. government funding commitments in excess of $600 million for the development of its portfolio products. PharmAthene's portfolio currently includes the following product candidates: • SparVax® - a next generation recombinant protective antigen (rPA) anthrax vaccine • Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection